Document Classification

Section Type: RESULTS

Text: Median progression-free survival (PFS ; primary end point) was 2. 86 months for patients treated with dacomitinib and 1. 91 months for patients treated with erlotinib (hazard ratio [HR] = 0. 66 ; 95 % CI, 0. 47 to 0. 91 ; two-sided P =. 012) ; in patients with KRAS wild-type tumors, median PFS was 3. 71 months for patients treated with dacomitinib and 1. 91 months for patients treated with erlotinib (HR = 0. 55 ; 95 % CI, 0. 35 to 0. 85 ; two-sided P =. 006) ; and in patients with KRAS wild-type/EGFR wild-type tumors, median PFS was 2. 21 months for patients treated with dacomitinib and 1. 84 months for patients treated with erlotinib (HR = 0. 61 ; 95 % CI, 0. 37 to 0. 99 ; two-sided P =. 043).